Kornimate/medical-research-clean huggingface dataset:
mpowered messages: tailored mobile messages to enhance weight loss for teens

Conditions: Obesity

Summary: obesity affects millions of american children and increases their risk of adult obesity, a myriad of serious illnesses, increased healthcare costs, and premature death. it is vital to find ways to reverse this epidemic. multidisciplinary behavioral weight management programs offer the promise of effectively treating childhood obesity. however, participants in such programs often find it challenging to follow recommended treatment plans and frequently drop out from programs without completing them. the proposed project aims to address these problems through frequent contact with patients between office visits. this interim contact will be achieved by automatically sending tailored messages to the mobile phones of adolescents enrolled in a multidisciplinary weight management program (the mpower program), as an adjunct to clinic visits. the investigators hypothesize that program participants who receive the tailored text messages will experience lower attrition rates, increased treatment adherence, and greater weight loss compared to those program participants who do not receive the messages.


Eligibility criteria:
inclusion criteria: * bmi ≥ 95th percentile for sex and age according to cdc growth charts * enrollment in the mpower program * at least one parent willing and able to participate in the mpower program with the adolescent * absence of any major medical illness, disability, or moderate/severe mental disorder (e.g., liver disease, renal failure, cancer, bipolar disorder) exclusion criteria: * presence of any major medical illness, disability, or moderate/severe mental disorder (e.g., renal failure, cancer, bipolar disorder) * physical, mental, or cognitive handicaps that prevent participation * chronic use of medications that may affect study outcomes (e.g., diuretics, oral steroids) * girls who are pregnant, planning to become pregnant in the next 6 months, lactating, or within 6 months postpartum

Keywords: obesity treatment adolescents text messages mobile phones multidisciplinary
validity and reliability of the six-minute peg board and ring test in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the aim of the study was to evaluate the validity and reliability of 6-pbrt in patients with rheumatoid arthritis and to determine the applicability of the test for this population.

rheumatoid arthritis (ra) is a systemic, inflammatory disease that causes pain and joint involvement. pain, loss of range of motion, and decreased muscle strength lead to loss of function in patients with ra. hand grip and generalized muscle weakness in patients cause decreased upper extremity functions. a study found that the upper extremity functional capacity of ra patients was lower than that of healthy individuals. in routine evaluations of rheumatoid arthritis patients, rough and fine grip strength measurements are made, but these measurements do not provide sufficient information about upper extremity functional exercise capacity. rehabilitation programs aim to improve upper extremity function, therefore, valid and reliable methods are needed to determine upper extremity function in ra patients and to measure the effectiveness of rehabilitation programs. the six-minute peg board and ring test (6-pbrt) is a valid, reliable, useful, practical and easy-to-apply test that evaluates upper extremity endurance without support in patients with chronic obstructive pulmonary disease and asthma and in healthy individuals (5-7). studies have determined that the total number of rings in 6-pbrt has a positive relationship with upper extremity daily living activities in copd and asthma patients. six-pbrt is frequently used in the evaluation of upper extremity exercise capacity and endurance without support and in determining the effectiveness of rehabilitation programs. the validity and reliability of 6-pbrt, which is used in the evaluation of functional upper extremity exercise capacity in different diseases, has not been investigated in patients with ra. the arm ergometer test is also a gold standard method used to evaluate upper extremity exercise capacity. therefore, it was planned to use the arm ergometer test as a criterion measure for the validity of 6-pbrt in our study. the aim of this study was to evaluate the validity and reliability of 6-pbrt in patients with rheumatoid arthritis and to determine the applicability of the test for this patient population.

Eligibility criteria:
inclusion criteria: * patients diagnosed with rheumatoid arthritis, * ages of between 18-75 years, * patients who volunteer to participate in the study will be included in the study. exclusion criteria: * serious cardiopulmonary, neurological, neuromuscular, orthopedic and other systemic diseases or other diseases affecting physical functions, * participated in a planned exercise program in the last three months, * cognitive impairment that will cause difficulty in understanding and following exercise test instructions, * contraindications to exercise testing or exercise training according to the american sports medicine association will not be included in the study.

Keywords: exercise capacity rheumatoid arthritis hand-grip
longterm outcome of the delta iii inverse prosthesis

Conditions: Rotator Cuff Tear Arthropathy

Summary: the aim of the study is to describe the results after \> 10 years due to a prosthesis implant.

the aim of the study is to measure the gain of the benefit in function an painreduction which the patient yields with this type of prosthesis in a longterm (\> 10 years )outcome. additionally the long-term results will be compared with the mid-term results and the literature. furthermore the complications since the mid-term measurement time point will be determined.

Eligibility criteria:
inclusion criteria: * implantation of a delta iii - prothesis * timeframe (oct 1998 - dec 2002) * delta-pectoral approach * written informed consent exclusion criteria: * implantation because of a revision * complaints, which make it difficult to follow instructions or even prevent
prismatic lenses and tdcs in neglect

Conditions: Stroke, Ischemic

Summary: the goal of this study is to to evaluate the effect and feasibility of a rehabilitation protocol with prismatic lenses associated with tdcs, compared to a prismatic lens rehabilitation protocol associated with sham stimulation, in reducing the signs of neglect in a group of patients with spatial heminegligence following ischemic stroke of the right hemisphere. the secondary objective is to evaluate the impact of this rehabilitation protocol on functional outcome.


Eligibility criteria:
inclusion criteria: * age \>18 years * ischemic stroke * hospitalization within 90 days of the event exclusion criteria: * heamorrhagic stroke * history of neurological disease * history of psychiatric disease * use of alchool and drugs

Keywords: stroke neglect tdcs prismatic lenses
the efficacy of adapted yoga in managing psychosocial risk in implantable cardioverter defibrillator (icd) patients

Conditions: Cardiac Arrhythmias

Summary: psychosocial risks are significant in the management of patients with cardiovascular disease and implantable cardioverter defibrillators (icd) devices. this is a randomized, controlled, clinical study. the hypothesis is that adapted yoga (vs. usual care) will significantly reduce psychosocial risks (e.g. anxiety and depression symptoms) and improve the quality of life in icd patients. the specialized, real-time data, collected by the device provides a unique look at the electrophysiological parameters of each patient's heart.

all intervention data will be analyzed to determine the statistical significance of the data, and to accept or reject the hypothesis. in addition, the researcher will conduct supplemental interviews with patients who have lived with the implantable cardioverter defibrillator (icd) device for at least six months and who are not in the intervention. the qualitative data gathered from these interviews will document concepts of illness and healing and general beliefs about mind-body interventions.

Eligibility criteria:
inclusion criteria: * receipt of implantable cardioverter defibrillator for 6 weeks or more * must be 18 or more years of age exclusion criteria: * patients requiring more than 48 hours of hospitalization for implantation * mental incompetence (dementia) * physician's contra-indication

Keywords: randomized clinical control trial complementary and alternative medicine yoga electrophysiology implantable cardioverter defibrillator psychosocial anxiety self-compassion anti-tachycardia pacing events
effect of spgb on icp and oxygenation of cerebral venous outflow in craniotomy for cerebral tumors.

Conditions: Cerebral Tumor

Summary: this study aims to investigate the effect of sphenopalatine ganglion block on icp and arterio- jugular venous oxygen difference (ajvdo2) and jugular bulb oxygen saturation (sjvo2). throughout this study, the efficacy of sphenopalatine ganglion block as scalp block in craniotomy operation will be assessed, and the effect of spgb on cerebral hemostasis during craniotomy will be evaluated by monitoring of both icp, ajvdo2 and sjvo2.

this study was performed in the neurosurgical operating room and included 52 patients allocated into two groups: the treatment group (block group) and the control group (non-block group). 26 patients enrolled in block group and 26 patients in non-block group. intraoperative icp monitoring by subdural icp monitors will be done every 20 minutes in both block and non- block groups until craniotomy has been occurred, then at the time of closure of the dura . arterio- jugular venous oxygen difference and jugular venous bulb oxygen saturation changes will be recorded every 20 minutes in block and non- block groups throughout time of the surgery till closure of the dura.

Eligibility criteria:
inclusion criteria: * patients who prepared for a neurosurgical intervention for elective supratentorial tumor removal * asa 1 and 2 * age above 18 years and below 65 years * fully conscious patients. exclusion criteria: * patients with cardiovascular and respiratory diseases * pregnancy * patient refusal

Keywords: spgb icp cbf avdo2
an expanded access protocol for sebelipase alfa for patients with lysosomal acid lipase deficiency

Conditions: Lysosomal Acid Lipase Deficiency

Summary: this is an open-label, multicenter expanded access protocol to allow patients with a confirmed diagnosis of lysosomal acid lipase (lal) deficiency in the united states (us), access to sebelipase alfa (recombinant lysosomal acid lipase \[rhlal\]) until commercial product is available. patients enrolled in the expanded access protocol will receive 1 mg/kg intravenous infusions of sebelipase alfa every other week.


Eligibility criteria:
inclusion criteria: 1. patient is ≥ 8 months of age at commencement of treatment with sebelipase alfa. 2. patient has a confirmed diagnosis of lal deficiency. 3. patient or patient's parent or legal guardian (if applicable) consents to participation in the study. if the patient is of minor age, he/she is willing to provide assent where required per local regulations, and if deemed able to do so. 4. male and female patients of childbearing potential must use a highly reliable method of birth control (expected failure rate less than 5% per year) from the time they commence treatment through 4 weeks after the last dose of sebelipase alfa. 5. women of childbearing potential must have a negative serum pregnancy test at commencement of treatment with sebelipase alfa. exclusion criteria: 1. women who are nursing or pregnant. 2. patients who received an investigational product within 30 days (for a small molecule) or 60 days (for a biologic) of commencing treatment, and which in the opinion of the investigator or sponsor, may negatively impact patient safety. 3. patients who have received sebelipase alfa as part of a clinical trial that is currently active. 4. patients with known hypersensitivity to eggs.

Keywords: cholesteryl ester storage disease acid lipase disease cholesterol ester hydrolase deficiency lipa deficiency wolman disease lysosomal storage disease
music during eswl for half treatment

Conditions: Urolithiasis

Summary: the aim of this study is to evaluate if music listening relieves pain and discomfort during extracorporeal shock-waves lithotripsy (eswl).

patients undergoing eswl and interested in music listening are randomly divided in two groups: patients in group a listen to music during the first part of the treatment (first 1800 sw), patients in group b during the second part. at the end of the treatment patients are asked to fill in a questionnaire. they are asked if they were pleased to have had the opportunity to listen to music during eswl, if they would like to listen to music again in case of further treatments, if they consider music helpful in relieving pain and discomfort during eswl. patients are also asked to mark their level of pain during each part of the treatment on a visual analogue scale (vas) for pain.

Eligibility criteria:
inclusion criteria: * all patients undergoing eswl from february 2011 to october 2012 and interested in music listening exclusion criteria: * contraindication to eswl * no interest in music listening * \ 80 years

Keywords: urolithiasis kidney calculi lithotripsy pain management music
effect of ffp2 masks on peripheral oxygen saturation and pulse rate during the covid-19 pandemic

Conditions: Hypoxia; Hypercapnia; COVID-19 Pandemic

Summary: aim of this research is to evaluate the effects of ffp2/n95 masks on peripheral oxygen saturation and pulse rate in dental professionals


Eligibility criteria:
inclusion criteria: * dental professionals exclusion criteria: * subjects not signing informed consent * subjects unable to wear facemasks due to underlying conditions
metastatic tumor research and outcomes network

Conditions: Metastatic Spine Tumor

Summary: the registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and hrqol outcomes specific for patients with metastatic spine tumor(s).

to prospectively determine the prognostic variables (clinical, diagnostic, and therapeutic) within patients diagnosed with metastatic spine tumor(s) that are associated with: * patient reported outcomes (hrqol) * morbidity data * local tumor control * survival outcome measures: variables which will be collected in the registry that are applicable to patients with metastatic spine tumor include: * • patient details * details of previous treatment * diagnosis * symptoms * treatment details for the index target * imaging information the following outcome measures will be collected: * patient reported outcomes: * euroqol eq-5d-3l * euroqol eq-5d vas - quality of life * neck pain numeric rating scale (nrs) * arm pain nrs * back pain nrs * leg pain nrs * sosgoq * patient assessment * ambulation * pain medication * nutritional status tool (pg-sga©) * morbidity data * local disease recurrence data * overall survival data

Eligibility criteria:
inclusion criteria: * patient 18 or older. * patient diagnosed with a metastatic tumor of the spine * informed consent obtained, i.e.: * ability to understand the content of the patient information/icf * willingness and ability to participate in the registry according to the registry plan * signed and dated ec/irb approved written informed consent (if consent is required by the ec/ irb at the registry site) exclusion criteria: • patient diagnosed with a primary tumor of the spine.

Keywords: registry spine surgery medical oncology radiation oncology neoplasms metastasis chemotherapy radiation therapy tumor markers
direct or subacute coronary angiography in out-of-hospital cardiac arrest

Conditions: Out-of-Hospital Cardiac Arrest

Summary: the overall aim of this prospective, randomized study is to investigate whether acute coronary angiography (within 120 minutes) with a predefined strategy for revascularization, will improve 30-day survival in patients with out of hospital cardiac arrest with no signs of st-elevation on ecg after restoration of spontaneous circulation (rosc). the patients will be randomized to a strategy of immediate coronary angiography within 120 minutes or to a strategy of delayed angiography that may be performed three days after the cardiac arrest.

the study is a prospective randomized open label multicenter study with a registry follow up in which patients with out of hospital cardiac arrest without st-elevation on their first ecg will be randomized to either a strategy of immediate coronary angiography (treatment group) with possible coronary intervention or a strategy of delayed coronary angiography (control group). the study will include in total 1006 patients with restoration of spontaneous circulation (rosc). randomization will be done via a web-based module after ecg is taken at the first medical contact but no later than after arrival at the emergency room. coronary angiography should be performed within 120 minutes from randomization in the immediate angiography group. in the delayed angiography group, angiography with possible coronary intervention will be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. this strategy is in accordance with standard practice. in case of recurrent chest pain, st elevation, circulatory instability or cardiogenic shock, cross over to early angiography may occur. the quality of life and health economics will be evaluated at 6 months. the patients will undergo extensive neurocognitive tests and health instruments, these will be analyzed and presented.

Eligibility criteria:
inclusion criteria: * witnessed out of hospital cardiac arrest * restoration of spontaneous circulation (rosc) \>20 minutes * coronary angiography is expected to be performed within 120 minutes from inclusion and randomization at hospital exclusion criteria: * patient age \<18 years * obvious extracardiac genesis of cardiac arrest such as trauma, hemorrhagic shock, and / or asphyxia (eg drowning, suffocation, hanging, exposure to fire smoke) * terminally ill patients with a life expectancy of less than 1 year * patients with st-elevation * known pregnancy * patient awake gcs \>8 (glasgow coma scale)
the beneficial effect of vitamin d supplement to peg interferon alpha 2a or to telbivudine monotherapy in patients with chronic hepatitis b virus (hbv) infection

Conditions: Hepatitis B Virus

Summary: abstract telbivudine is a potent inhibitor of hbv but, due to a low genetic barrier to resistance, a high incidence of resistance has been observed in patients with high baseline levels of replication and in those with detectable hbv dna after 24 weeks of therapy (a1). telbivudine might be used in patients with good predictors of response (hbv dna \<2 x 106 iu/ ml, i.e. approximately 107 copies/ ml, or 6.3 log 10 iu/ ml at baseline) with verification of hbv dna suppression below detection in real time pcr assay at 24 weeks.(easl guidelines for hbv 2009) the therapy of pegylated-interferon-alpha-2a is considered as the standard of care for patients with chronic hepatitis b viral infection. however, recent study by buster et al showed that a sustained viral response (svr less than 2000 iu.ml at 6 months after treatment)) is obtained in 8 % of patients with genotype d, 30% genotype a, and 20-25% genotypes b or c (47). vitamin d is a potent immune-modulator; and has been shown to improve svr in combination with peg interferone in patients with chronic hcv viral infection (48). the impact of vitamin d on virologic response rates of interferon-based treatment of chb is unknown. the aim of this study therefore was to assess whether vitamin d, added to the conventional peg therapy in chb, or to nucleotide analogues could improve the treatment efficacy


Eligibility criteria:
inclusion criteria: * patients were eligible if they had been hbsag positive for at least 6 months, * patients were hbeag positive or negative, * patients had increased serum alt levels between 1 and 10 times the upper limit of normal (uln), * patients had serum hbv-dna levels greater than 1.0 x 10e5 copies/ml (2.0 x 10e4 iuml), and * patients had findings on a liver biopsy within the preceding 12 months that were consistent with the presence of chronic hepatitis b. exclusion criteria: * decompensated liver disease, * antiviral therapy within 6 months before randomization, * viral co-infections (hepatitis c virus, hepatitis delta virus, or human immunodeficiency virus), or * pre-existent neutropenia or thrombocytopenia.

Keywords: hbv vitamin d pegiterferon telbivudine
efficacy and safety of omalizumab in chronic idiopathic urticaria

Conditions: Chronic Idiopathic Urticaria

Summary: the study is designed to assess the efficacy and safety of monthly injections of omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic idiopathic urticaria for 3 months * failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin exclusion criteria: * physical or cholinergic urticaria * past treatment in omalizumab i nprevious year * parasitic infection * malignancy in last 5 years * known sensitivity to omalizumab